Professor Hornicek, the President of the International Society of Limb Salvage (ISOLS), and His Delegation Visited Bone Oncology Dept of Shanghai General Hospital for an Academic Exchange

国际保肢协会主席Hornicek教授一行来访上海市一骨肿瘤科学术交流

As summer colors deepen and greenery flourishes, on May 24th, internationally renowned bone tumor expert Professor Francis Hornicek, the current Chairman of the International Society of Limb Salvage (ISOLS) and Director of Orthopedics at the University of Miami, along with Professor Duan Zhenfeng from the Orthopedics Institute at the University of Miami, visited the Bone Oncology Department of Shanghai General Hospital for academic exchange.

Over the years, Professor Hornicek has maintained a good cooperative relationship with the Bone Oncology Department of Shanghai General Hospital and served as a member of the Academic Committee of the Shanghai Bone Tumor Research Institute. During this visit, both sides not only conducted extensive and in-depth discussions on bone tumor limb salvage protocols, surgical techniques, as well as the latest advancements in basic scientific research and clinical translation, but also reached a preliminary consensus on future collaborative research plans.

During the morning round, Professor Cai Zhengdong, on behalf of the Bone Oncology Department of Shanghai General Hospital, first extended a warm welcome to Professor Hornicek and his delegation, and briefly introduced the development of the department in recent years. Following that, Director Sun Wei and Professor Hua Yingqi provided detailed explanations on the medical practices and scientific research achievements of the department. They also reached a preliminary consensus with the two professors on strengthening clinical technical exchanges and promoting scientific research cooperation, laying a solid foundation for further cooperation in the future.

Professor Hornicek and Director Cai exchanged signed copies of the translation of "Osteopathology."

Accompanied by Director Ma Xiaojun, two professors conducted a joint teaching grand rounds. The two professors engaged in brief exchanges with the patients currently hospitalized, inquiring thoroughly about the conditions of several preoperative patients with complex condition. The team's rigorous work attitude and service spirit left a profound impression on the patients.

After the ward rounds, both sides jointly conducted a case discussion, exchanged and shared their insights on surgical techniques for bone tumor, medical treatment strategies, and new international frontier technologies, which provided suggestions for the treatment plans of several difficult and complex patients.

The Orthopedic Oncology Department of Shanghai General Hospital has been committed to building a high-level research-oriented discipline that is first-class in China and internationally renowned, and actively seeks exchanges and cooperation with outstanding physicians and researchers at home and abroad. The visit of the two foreign professors not only brought international cutting-edge academic concepts and technologies to the department, but also injected new vitality into its future development. We firmly believe that through exchanges and cooperation with peers at home and abroad, the Orthopedic Oncology Department of Shanghai General Hospital will better serve patients and promote continuous progress and development in the field of Orthopedic Oncology.

Department Introduction

The Department of Orthopedic Oncology of Shanghai General Hospital was founded by Professor Cai Zhengdong, a renowned expert in orthopedics and bone tumors. It is one of the major centers for the diagnosis and treatment of bone and soft tissue tumors in China, specializing in the integrated discipline of bone tumor diagnosis, treatment, research, rehabilitation, and prevention. Its characteristic specialties include surgical resection and reconstruction of malignant bone tumors (extremities, pelvis/sacrum, spine), limb-saving treatment for pediatric malignant bone tumors, comprehensive/minimally invasive treatment for bone metastatic tumors, comprehensive treatment for advanced sarcomas, and clinical trials of new drugs. Both total treated cases and clinical efficacies have reached leading  levels domestically and internationally. The department is equiped with state-of -the - art medical devices. It adopts advanced concepts of surgical comprehensive treatment by providing warm humanistic care to serve numerous patients with bone tumors and bone diseases.

After ten years of construction, our department has become a key discipline of Shanghai General Hospital. It has launched a series of research projects focusing on important directions such as new surgical resection and reconstruction techniques for bone tumors, new instruments for limb-saving surgery in children, the establishment of a precision treatment system for bone tumors, and clinical researches on new treatment regimens for advanced sarcomas. A comprehensive research platform has been established, encompassing cellular and molecular researches, patient-derived xenograft (PDX) models, medical-engineering intersections, and clinical trials. In the past five years, the department has obtained over 30 national and provincial research grants, including the National Key Research and Development Program, the National Natural Science Foundation of China, and various provincial and ministerial grants. It has also won multiple talent programs such as the Shanghai Leading Talents Program, the Shanghai Oriental Talent Program, the Shanghai Youth Top Talents Program, the Shanghai Silver Snake Award, the Shanghai Science and Technology Rising Star Program, and the Shanghai Pujiang Talents Program. The department's achievements in improving the resection and reconstruction outcomes of pelvic ring tumors have received the First Prize of Chinese Medical Science and Technology Award and the Second Prize of Shanghai Science and Technology Progress Award. Researches on standardized surgery and precision treatment for osteosarcoma has also been awarded the First Prize of the Ministry of Education's Science and Technology Progress Award and the Second Prize of Shanghai Science and Technology Progress Award. The research results have been published in top-class journals such as PNAS, Nature Communications, Advanced Science, and Oncogene. New targeted drugs for osteosarcoma, innovative surgical instruments for pelvic tumors, and equipment and reagent kits for liquid biopsy of bone tumors have all been patented, all of which have obtained marketing approvals and further clinical trials are ongoing. The department has taken the lead in multiple domestic multicenter clinical studies, especially the first wave innovative clinical trials in China such as TILs cell therapy for osteosarcoma, umbrella trials of precision for osteosarcoma, and oncolytic virus combined with TCR-T therapy for bone and soft tissue sarcomas, which have improved the prognosis and quality of life for patients with bone tumors.